الفهرس | Only 14 pages are availabe for public view |
Abstract The study may prove that: CTCs allow early detection of ovarian cancer even in asymptomatic patients CTCs are well correlated with FIGO stage CTCs are absent in benign and borderline ovarian tumors. CTCs can be used to discriminate between early and late FIGO stage at a cutoff level of > 0.82 cell/ul, with 66.7% sensitivity, 90.9% specificity, 88% PPV and 73.2% NPV (AUC = 0.65 & p-value = 0.076). CTCs can be used to discriminate between patients with optimum debulking and patients without optimum debulking at a cutoff level of < 1.9 cell/ul, with 100% sensitivity, 60% specificity, 71.4% PPV and 100% NPV (AUC = 0.65 & p-value = 0.063). |